桂哌齐特联合厄贝沙坦治疗早期糖尿病肾病临床观察

Clinical Observation of the Combined Therapeutic Effect of Cinepazide Maleate and Irbesartan on Early Diabetic Nephropathy

目的:评价桂哌齐特联合厄贝沙坦治疗早期糖尿病肾病的临床疗效。方法:选择糖尿病合并早期糖尿病肾病住院病例60例,随机分为两组,每组30例。A组给予厄贝沙坦治疗,B组在厄贝沙坦治疗的基础上加用马来酸桂哌齐特治疗,疗程14 d,观察治疗前后的24 h尿微量白蛋白(24hUmAlb)和C反应蛋白(CRP)的变化。结果:两组治疗后24hUmAlb均较治疗前下降(A组P<0.05,B组P<0.01),B组下降幅度较A组更大;两组治疗前CRP均高于正常,A组治疗前后CRP无明显变化(P>0.05),B组治疗后CRP水平较治疗前明显下降(P<0.01)。结论:桂哌齐特联合厄贝沙坦治2型糖尿病合并早期糖尿病肾病疗效显著,可以改善血管内皮功能,减少24hUmAlb。

Objective ： To observe the combined therapeutic effect of einepazide maleate （ CM ） and irbesartan on early diabetic nephropathy. Method： Sixty diabetic patients with early diabetic nephropathy were randomly divided into two groups including treatment group （group B） and control group （group A） with 30 cases in each. Group A received irbesartan,while group B received the combined treatment of CM and irbesartan for 14 days. The levels of 24h UmAlb and C reactive protein （CRP） were tested pre-and post-therapy in both groups. Result： The levels of 24h UmAlb decreased in both groups after therapy （ group A with P 〈 0. 05 and group B with P 〈 0. 01 ）. The plasma levels of CRP were higher in both groups before therapy. The plasma levels of CRP decreased in group B after therapy （ P 〈 0. 05 ）, while there was no significant change in group A after therapy （ P 〉 0.05 ）. Conclusion： Combined therapy of CM and irbesartan can improve the vascular endothelial function and decrease 24h UmAlb in diabetic patients with early diabetic nephropathy.